Establishment of a R-Sphere labelled immunoassay platform and its rapid combined quantitative detection of ketamine and morphine in serum

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-03-07 DOI:10.1016/j.cca.2025.120225

Binbin Zhao , Aolin Zhu , Qian Zhang , Ziyue Li , Yongwei Zhang , Meng Liu , Hao Zhou , Tingwei Liu , Xuelei Zhou , Jiutong Li , Jun Zhao , Xinxia Li

{"title":"Establishment of a R-Sphere labelled immunoassay platform and its rapid combined quantitative detection of ketamine and morphine in serum","authors":"Binbin Zhao , Aolin Zhu , Qian Zhang , Ziyue Li , Yongwei Zhang , Meng Liu , Hao Zhou , Tingwei Liu , Xuelei Zhou , Jiutong Li , Jun Zhao , Xinxia Li","doi":"10.1016/j.cca.2025.120225","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><div>Ketamine and morphine are among the most commonly abused drugs. Ketamine is classified as a new psychoactive substance, while morphine represents the opioid class. These two substances may exhibit synergistic or antagonistic effects in their pharmacological actions, and their combined abuse could lead to more severe health risks, such as respiratory depression. Therefore, simultaneous detection is crucial for comprehensive monitoring of drug abuse. This study developed a test strip capable of detecting both ketamine (KET) and morphine (MOP) in serum, utilizing Raman spectroscopy technology to meet the needs of various application scenarios.</div></div><div><h3>Methods</h3><div>A mixture of Raman microsphere-labelled KET and MOP antibodies was mixed with a mixed standard solution of KET and MOP and added dropwise to the sample pad of the prepared KET and MOP co-assay test strip, chromatographed for 10 min, and then the Raman spectra and Raman signals at the T-line were detected using a Raman spectrometer.</div></div><div><h3>Results</h3><div>The KET and MOP showed good correlation with the Raman signal response values in the concentration ranges of 0.0–100.0 ng/mL and 0.0–4.0 ng/mL, and the limits of detection (LODs) were 1.1986 ng/mL and 0.0113 ng/mL with the coefficients of variation (CV) of less than 10 %, the recoveries were in the ranges of 90 %-110 %, and interfering substances had no effect on the detection results.</div></div><div><h3>Conclusion</h3><div>In this study, we developed a method for the quantitative detection of KET and MOP based on the spectroscopic properties of Raman microsphere (R-Sphere) and the principle of competitive immunity, which has the advantages of simple operation, rapidity, high sensitivity, and the possibility of combined detection, which makes the detection efficiency greatly improved.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"571 ","pages":"Article 120225"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125001044","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims

Ketamine and morphine are among the most commonly abused drugs. Ketamine is classified as a new psychoactive substance, while morphine represents the opioid class. These two substances may exhibit synergistic or antagonistic effects in their pharmacological actions, and their combined abuse could lead to more severe health risks, such as respiratory depression. Therefore, simultaneous detection is crucial for comprehensive monitoring of drug abuse. This study developed a test strip capable of detecting both ketamine (KET) and morphine (MOP) in serum, utilizing Raman spectroscopy technology to meet the needs of various application scenarios.

Methods

A mixture of Raman microsphere-labelled KET and MOP antibodies was mixed with a mixed standard solution of KET and MOP and added dropwise to the sample pad of the prepared KET and MOP co-assay test strip, chromatographed for 10 min, and then the Raman spectra and Raman signals at the T-line were detected using a Raman spectrometer.

Results

The KET and MOP showed good correlation with the Raman signal response values in the concentration ranges of 0.0–100.0 ng/mL and 0.0–4.0 ng/mL, and the limits of detection (LODs) were 1.1986 ng/mL and 0.0113 ng/mL with the coefficients of variation (CV) of less than 10 %, the recoveries were in the ranges of 90 %-110 %, and interfering substances had no effect on the detection results.

Conclusion

In this study, we developed a method for the quantitative detection of KET and MOP based on the spectroscopic properties of Raman microsphere (R-Sphere) and the principle of competitive immunity, which has the advantages of simple operation, rapidity, high sensitivity, and the possibility of combined detection, which makes the detection efficiency greatly improved.

查看原文本刊更多论文

r球标记免疫分析平台的建立及其血清氯胺酮和吗啡快速联合定量检测

背景和目的氯胺酮和吗啡是最常被滥用的药物。氯胺酮是一种新的精神活性物质，而吗啡是阿片类药物。这两种物质在药理作用中可能表现出协同或拮抗作用，它们的联合滥用可能导致更严重的健康风险，如呼吸抑制。因此，同时检测对药物滥用的综合监测至关重要。本研究利用拉曼光谱技术，开发了一种能够同时检测血清中氯胺酮（KET）和吗啡（MOP）的试纸条，以满足多种应用场景的需求。方法将拉曼微球标记的KET和MOP抗体的混合物与KET和MOP的混合标准溶液混合，滴加到制备的KET和MOP共检测试纸的样品垫上，色谱10 min，用拉曼光谱仪检测拉曼光谱和t线处的拉曼信号。结果KET和MOP在0.00 ~ 100.0 ng/mL和0.0 ~ 4.0 ng/mL浓度范围内与拉曼信号响应值具有良好的相关性，检出限分别为1.1986 ng/mL和0.0113 ng/mL，变异系数小于10%，加样回收率在90% ~ 110%之间，干扰物对检测结果无影响。结论本研究基于拉曼微球（R-Sphere）的光谱特性和竞争免疫原理，建立了一种用于KET和MOP定量检测的方法，该方法操作简单、快速、灵敏度高，且可联合检测，大大提高了检测效率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.